AtriCure, Inc. (ATRC) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products.
Is AtriCure, Inc. stock overvalued or undervalued in 2026?
AtriCure, Inc. (ATRC) trades at 289× earnings (P/E), against a median of 30.4× across the 246 healthcare companies above $2bn in Kaplio's universe. No valuation verdict: it earns very little for its market value, and with such small earnings there is no reliable reference price.
Kaplio overview: AtriCure, Inc.
Market cap $3B · 52 weeks $26 – $62 (2 % below the high) · P/E 289× · 2027 expected P/E 146× · Dividend none · Next earnings November 3, 2026 · expected EPS $-0.05 · Closing price, Oct 30 · accounts published Jul 23.
- Valuation: P/E 288.6× (no verdict).
- Business: ROIC 2 % (weak).
- Balance sheet: Net cash/EBITDA 4.9× (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it earns very little for its market value (it trades at 289 times earnings; its sector median, 30.4).
What matters in pharma: 3 of 4 pass
- ROIC 2.0 %, fails.
- R&D / Revenue 16.9 %, passes.
- Gross margin 74.4 %, passes, near the threshold.
- Net debt / EBITDA −4.9×, passes.
Against its peers (reference peers) — AtriCure, Inc.: P/E 289×; EV/EBITDA 80.0×; ROIC 2.0 %; $3.1B. LivaNova PLC (P/E 23.3×; EV/EBITDA 19.3×; ROIC 10.2 %; $4.3B), Edwards Lifesciences Corporation (P/E 52.9×; EV/EBITDA 32.1×; ROIC 10.2 %; $53.0B), Boston Scientific Corporation (P/E 17.8×; EV/EBITDA 13.5×; ROIC 10.5 %; $60.8B).
Profitability
| Return on Equity | 2.14% |
| Return on Invested Capital | 2.04% |
| Return on Assets | 1.56% |
| Gross Margin | 76.16% |
| Operating Margin | 2.44% |
| Net Margin | 1.85% |
Financial Health
| Debt / Equity | 0.14 |
| Current Ratio | 4.22 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 7.34 |
Price Performance
| 1 month | +11.08% |
| 3 months | +58.19% |
| Year-to-date | +54.83% |
| 1 year | +77.28% |
| 3 years | +67.44% |
| 5 years | -21.11% |
| 10 years | +265.67% |
Related companies: BSX · LIVN · MDT · EW
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of ATRC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks